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In this issue, Schlessinger and his colleagues (Yuzawa et al., 2007) describe crystal struc-
tures of the complete extracellular region of the Kit receptor tyrosine kinase, both alone 
and in complex with its activating ligand, stem cell factor (SCF). The structures explain 
how SCF drives dimerization of the receptor. They also reveal important receptor-receptor 
contacts that may explain how several Kit mutations lead to cancer.Aberrant signaling by growth fac-
tor receptor tyrosine kinases (RTKs) 
is responsible for many human 
diseases, from cancer to develop-
mental and metabolic defects. The 
relevant pathologies are often asso-
ciated with receptor mutations or 
inappropriate expression of growth 
factors (Robertson et al., 2000). In 
either case, unraveling the mecha-
nisms of RTK signaling should help 
to illuminate useful avenues for the 
design of new therapeutics.
An excellent example is pro-
vided by Kit, a class III RTK that 
is expressed by many cell types 
including hematopoietic stem cells. 
Kit is activated by a cytokine ligand 
known as stem cell factor (SCF). 
Pathological mutations in both 
the extracellular and intracellular 
domains of Kit have been identi-fied. Gain-of-function mutations 
are associated with gastrointesti-
nal stromal tumors and other can-
cers, whereas mutations that cause 
loss of function lead to piebaldism, 
a disorder of melanocyte devel-
opment (Robertson et al., 2000). 
Structural studies of the intracellu-
lar domains of Kit and other class III 
RTKs explain how both inactivating 
and activating mutations are likely 
to achieve their effects (Robertson 
et al., 2000). Many of the activat-
ing Kit mutations associated with 
gastrointestinal stromal tumors are 
found in the intracellular “juxtamem-
brane” region of the receptor. This 
~35 amino acid region, between 
the transmembrane helix and the 
intracellular domain, interacts inti-
mately with the kinase domain and 
stabilizes an inactive configuration, Cell 13thus “autoinhibiting” the receptor 
(Hubbard, 2004). Many clinically 
observed mutations that activate 
Kit and other class III receptors are 
predicted to disrupt these autoin-
hibitory interactions. In addition to 
these intracellular juxtamembrane 
mutations, clinically important acti-
vating mutations are also found in 
the membrane-proximal part of the 
Kit extracellular region.
Now, in this issue of Cell, Schless-
inger and his colleagues (Yuzawa et 
al., 2007) describe the first structural 
view of extracellular membrane-
proximal interactions between two 
receptors in an activated RTK dimer. 
Structures of both the complete Kit 
extracellular region and the dimeric 
(activated) form induced by SCF pro-
vide explanations (or at least clear 
hypotheses) for how a variety of acti-0, July 27, 2007 ©2007 Elsevier Inc. 213
figure 1. Interactions of the Kit Dimer
When stem cell factor (SCF) induces dimerization of the Kit extracellular region, immunoglobulin (Ig)-like domains 1, 2, and 3 (D1-D3) remain un-
changed, whereas D4 and D5 become reoriented to face each other across the dimer interface. (Left) This structure shows a modeled Kit dimer 
with two free Kit molecules docked onto their SCF-binding sites. (Middle) This structure shows the actual SCF-induced Kit dimer (Yuzawa et al., 
2007), in which the two D4 and D5 domains in the dimer are in close proximity. Without reorientation of the D4 and D5 domains, the receptors in the 
dimer are separated by 75 Å at the membrane. Following D4/D5 reorientation, their C termini are separated by just 15 Å—a reasonable separation 
if the transmembrane α helices also interact intimately with one another. (Right) For comparison is shown a structural representation of a dimer of 
the extracellular region of the epidermal growth factor receptor (EGFR); dimer formation is induced by EGF. The membrane-proximal domain of this 
receptor (domain IV) has not been visualized directly in the dimer, but its location has been modeled based on known ligand-free configurations 
(Burgess et al., 2003). The studies of Kit by Yuzawa et al. (2007) suggest that weak interactions between membrane-proximal domains can play a 
critical role in defining the relative orientation of the two receptor tyrosine kinase molecules in the dimeric complex, and their close approach at the 
membrane surface, which is required for transmembrane signaling.vating and inactivating extracellular 
mutations influence Kit function. The 
structures also provide important 
insight into the normal mechanism 
of SCF-mediated Kit activation.
From previous studies of RTK 
activation, mechanisms of ligand-
induced dimerization can be clas-
sified into “ligand-mediated” and 
“receptor-mediated” groups. RTKs 
with immunoglobulin-like (Ig-like) 
domains in their extracellular regions 
(Kit has five) tend to fall into the 
ligand-mediated class in which a 
bivalent ligand binds simultaneously 
to two receptors and effectively 
“crosslinks” them into a dimer. In 
such cases, the growth factor ligand 
(alone or bound to an accessory 
molecule) directly forms the dimer 
interface (Stroud and Wells, 2004). A 
stark contrast to this scenario is pro-
vided by the epidermal growth fac-
tor (EGF) receptor family of RTKs, for 
which dimerization is entirely recep-
tor mediated (Burgess et al., 2003). 
In the EGF receptor, the bound 
growth factors are distant from the 
dimer interface, and their binding 214 Cell 130, July 27, 2007 ©2007 Elsevpromotes a dramatic domain rear-
rangement that exposes a dimeriza-
tion site in the extracellular region of 
the receptor.
The two new structures of the 
Kit extracellular region (Yuzawa 
et al., 2007) show that Kit is in the 
ligand-mediated camp. Indeed, this 
was anticipated given the five Ig-
like domains in the Kit extracellular 
region and the known dimeric four-
helix bundle structure of SCF. Each 
SCF molecule in the dimer binds to 
the first three Ig-like domains (D1, 
D2, D3) of Kit, nicely explaining clin-
ical and experimental loss-of-func-
tion mutations in this region (Liu et 
al., 2007; Yuzawa et al., 2007). Com-
paring the structures of the free and 
ligand-bound forms of Kit, Yuzawa 
et al. (2007) show that SCF binding 
induces no significant conforma-
tional changes in the D1-D3 region 
of Kit. Each individual domain is 
largely unaltered and the relation-
ship between the three Ig-like 
domains remains fixed whether or 
not ligand is bound, suggesting that 
the D1-D3 region of Kit is “poised” ier Inc.for binding to SCF. Interestingly, it 
is also a feature of the EGF receptor 
that growth factor binding does not 
induce significant conformational 
changes in the individual ligand-
binding domains (Burgess et al., 
2003).
An SCF dimer directly bridges two 
Kit molecules, and there are no con-
tacts between the two receptor mol-
ecules in the D1-D3 region (Figure 1; 
Liu et al., 2007; Yuzawa et al., 2007). In 
this sense, Kit dimerization is clearly 
ligand-mediated. However, there 
are clear contacts between the two 
receptor molecules in the membrane-
proximal region of the dimer, involving 
domains D4 and D5 (Yuzawa et al., 
2007). The left-most structure in Fig-
ure 1 shows how the ligand-mediated 
dimer would appear if the relationship 
between the five Ig-like domains was 
completely fixed. Comparison with 
the actual SCF/Kit dimer structure 
(Figure 1, middle; Yuzawa et al., 2007) 
reveals significant reorientation of the 
D4 and D5 domains that brings both 
domains very close to the dimer inter-
face. The two D4 domains in a dimer 
interact directly with one another, 
while D5-D5 interactions may be 
water mediated (Yuzawa et al., 2007). 
This “twist” in the receptor indicates 
that with Kit there are ligand-induced 
receptor-receptor interactions in an 
otherwise ligand-mediated recep-
tor dimer. How important are these 
receptor-mediated interactions? How 
much does this finding blur the dis-
tinction between ligand-mediated 
and receptor-mediated dimerization?
It has been shown that an anti-
body against domain D4 blocks 
SCF-induced Kit activation (Blech-
man et al., 1995), supporting the 
idea that the two D4 domains must 
be in close proximity in the active 
dimer. Yuzawa et al. (2007) note that 
the residues involved in direct D4-D4 
interactions, most prominently an 
intermolecular salt bridge, are con-
served in the D4 domains of other 
type III RTKs. Intriguingly, these 
residues are also conserved in the 
membrane-proximal Ig-like domains 
of type V (VEGF receptor) RTKs 
that have seven such domains. The 
authors demonstrate that mutating 
residues involved in the central D4-
D4 salt bridge impairs Kit signaling 
but without affecting dimerization 
itself. Indeed, earlier studies in solu-
tion showed that the absence of both 
the D4 and D5 domains does not 
reduce SCF-induced Kit dimerization 
(Lemmon et al., 1997). Thus, it seems 
clear that the D4-D4 interactions are 
important for Kit signaling, but they 
are not required for driving receptor 
dimerization per se. The interactions 
are centered on a single pair of salt 
bridges, which need not contribute 
positively to (and may actually even 
oppose) dimerization (Sheinerman 
and Honig, 2002). Such weak mem-
brane-proximal interactions between 
the two Kit molecules in a homodi-
mer are likely to be driven by SCF-
induced dimerization of the D1-D3 
region and could play an important 
role in defining the relative orienta-
tions of the two receptors (rather than aiding dimerization itself). An 
orientational role of this sort could 
be critical for linking Kit dimerization 
to activation of its kinase domain (via 
allosteric changes in the intracel-
lular juxtamembrane region). This 
notion of a specific configuration 
for the activation-competent dimer 
is also supported by the intriguing 
observation that almost all activating 
oncogenic mutations found in the Kit 
extracellular region (in gastrointes-
tinal stromal tumors and other can-
cers) map to the dimer interface of 
D5. Although the precise basis for 
the effects of these mutations is not 
clear, it seems likely that they pro-
mote aberrantly strong interactions 
between D5 domains in this region. 
Dimerization of Kit molecules harbor-
ing these mutations would therefore 
be pathologically receptor mediated 
(rather than ligand mediated), lead-
ing to elevated constitutive activity 
and promoting tumorigenesis.
Structural studies of other RTKs 
have left unclear the details of extra-
cellular membrane-proximal regions. 
No membrane-proximal interac-
tions are seen in the ligand-induced 
dimer of the fibroblast growth fac-
tor (FGF) receptor (Schlessinger et 
al., 2000), and the two molecules in 
the homodimer are predicted to be 
separated by ~40 Å at the membrane 
(compared with 15 Å for Kit). In the 
EGF receptor, crystallographic stud-
ies failed to discern the precise loca-
tion of the most membrane-proximal 
domain in the extracellular region, 
although some data suggest that it 
plays an important role in EGFR sig-
naling (Burgess et al., 2003), if not 
in actually stabilizing the receptor 
dimer. The EGFR dimer is depicted in 
Figure 1, with the hypothetical loca-
tion of its most membrane-proximal 
domain (domain IV) shown in outline. 
This model places the two recep-
tor molecules of the dimer 15–20 Å 
apart at the membrane and, together 
with crystallographic studies (Bur-
gess et al., 2003), suggests very Cell 13weak receptor-receptor interactions 
in this region. The SCF/Kit dimer 
structure presented in the Yuzawa et 
al. study presents us with a glimpse 
of the type of weak interactions that 
can be important in this part of RTK 
extracellular regions, and how they 
can play a critical role in normal and 
pathological RTK signaling. With 
clear views of RTK kinase domains 
(inactive and activated) and ligand-
binding domains, the challenge for 
the future is to understand precisely 
how these two regions are linked. 
The structure reported by Yuzawa et 
al. (2007) together with the structure 
of the Kit kinase domain (reviewed 
in Hubbard, 2004) leaves just 36 
intervening amino acids to account 
for (including the transmembrane 
domain) and brings us close to fully 
understanding the details of trans-
membrane signaling by this impor-
tant receptor.
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